US Passes Biosecure Act — A Game Changer For Indian Pharma
In a significant development for the global pharmaceutical industry, the US has enacted the Biosecure Act, which bans American companies from partnering with specific Chinese biotech firms. The primary goal of this legislation is to prevent potential misuse of US genomic data, prompting a major shift in the pharmaceutical supply chain.
The ban targets major players like BGI Genomics, MGI Tech, Complete Genomics, WuXi AppTec, and WuXi Biologics, pushing US drugmakers to look towards alternative suppliers. This new law is set to create a ripple effect across the industry, and could particularly benefit Indian contract development and manufacturing organisation companies.
India's CDMO sector, which currently holds just 2.7% of the global market, could see substantial growth. With China's CDMO industry dominating 8% of the global market, this change represents a significant opportunity for Indian companies to challenge China's stronghold and expand their share.
India Rating and Research Report indicated that 60% of listed Indian pharma firms are seeing increased business inquiries, while 33% expect the new legislation will drive substantial business growth. Over the next 12-18 months, Indian companies anticipate a surge in orders from the US, including new pilot projects and higher requests for quote.
However, Indian firms do have hurdles to clear. The sector is dealing with a lag in experience and a lack of advanced technology compared to their Chinese counterparts. Despite these challenges, the Act's potential is clear.
Several Indian pharmaceutical companies expect to reap rewards from this new development, as indicated in their first quarter concalls. Syngene International Ltd. noted that US companies are reassessing their supply chains and diversifying away from China, which is a significant opportunity for them. Laurus Labs acknowledges that while the shift will take time, it is a positive development for Indian CDMO opportunities.
Neuland Labs Ltd. reported that US customers are actively seeking alternatives to China, indicating a promising future regardless of the Act's final form. While, Divis Laboratories Ltd. is seeing a notable increase in opportunities, particularly for products in phases 2 and 3, driven by the passage of the Biosecure Act.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
